Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

(Alliance News) - Hedge fund Citadel has made a GBP305 million bet against pharmaceuticals firm GSK PLC, the biggest short position against the company in more than a decade, according to the ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce it has successfully completed ...

and there was also strong growth for HIV therapies sold by GSK's majority-owned ViiV Healthcare unit, which were up 21% to £1.68 billion in the three-month period. Berry is worried about the ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

The number of U.S. product recalls remained high during 2024 with more than 3,200 events recorded for the second consecutive year. According to Sedgwick brand protection's 2025 U.S. State of the ...

Adding fluorine to drug molecules can be tricky, but is often worthwhile. Rachel Brazil talks to the chemists trying to tame ...